AU Patent

AU2018202278B2 — SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia

Assigned to Boehringer Ingelheim International GmbH · Expires 2020-01-02 · 6y expired

What this patent protects

SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA Abstract The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellit…

USPTO Abstract

SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA Abstract The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018202278B2
Jurisdiction
AU
Classification
—
Expires
2020-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.